Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
19/03/2026
Germany's two-year government bond yield widened, rising by as much as 7.1 basis points to a session high of 2.517%.
Latest
3 m ago
Guotou Silver LOF: Suspended from the market opening on March 20th until 10:30.
3 m ago
Fortune Fund: Some of its funds listed on the Shenzhen Stock Exchange will change their ticker symbols starting from March 20th.
4 m ago
The China Securities Association is soliciting cultural construction and clean practice cases and advanced personal achievements from the entire industry.
4 m ago
Every AI Express of Every Economic News, Guotai Junan Securities issued a research report on March 19, giving a "buy" rating to Wanchen Group (300972.SZ). The reasons for the rating mainly include: 1) There is a divergence in the market regarding the continuous improvement of profit margins. We believe that maintaining a reasonable profit margin and strong competitive advantage is the core of the business. The company has solidified internal operations and supply chain for 25 years, enhancing intrinsic value; 2) Single-store performance gradually stabilizes in Q4 2025, and we expect the company to accelerate store openings in 2026; 3) The business model has strong blood-making ability and ample cash on hand; 4) There is a divergence in the market regarding the company's future growth prospects/development ceiling and the competitiveness/sustainability of the retail format. We believe that the current intrinsic value of the company is undervalued. (Daily Economic News)
5 m ago
Huasen Pharmaceutical: Independent Director Mr. Li Jiaming unfortunately passed away.
See all latest
